- When considering treatments, patients with glomerular disease and their caregivers gave highest priority to the health outcomes of kidney function, mortality, and need for dialysis or transplant.
- They also highly prioritized patient-reported outcomes such as life participation and fatigue that are not typically reported in clinical trials.
Newswise — Washington, DC (April 30, 2020) — Patients with glomerular disease and their caregivers highly prioritize kidney health and survival when it comes to treatment, but they also stress the importance of addressing factors related to life participation, fatigue, anxiety, and family impact. The findings come from a study that will appear in an upcoming issue of CJASN.
Glomerular diseases affect the glomeruli, or the tiny filters within the kidney where blood is cleaned, and patients can have a range of symptoms and unpredictable disease course. Patients commonly have poor kidney function, high blood pressure, protein or blood in their urine, and diabetes. They also have a higher chance of kidney failure, cardiovascular conditions, serious infections, broken bones, and even death. Affected patients and their caregivers have had little input into which health measures are assessed in clinical trials.
To identify and better understand key health outcomes that are important to these individuals, Simon Carter, MBBS (The University of Sydney) and his colleagues conducted the SONG-GD initiative, which included 16 focus groups of adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. The 101 patients and 33 caregivers in the study identified 58 outcomes. The 10 highest ranked outcomes were kidney function, death, dialysis or transplant requirement, life participation, fatigue, anxiety, family impact, infection and immunity, ability to work, and blood pressure. Three themes explained the reasons for these rankings: constraining day-to-day experience, impaired agency and control over health, and threats to future health and family.
“The reasons why these outcomes were so highly prioritized were because they restricted and limited people’s day-to-day living, reduced their ability to control or influence their own health, and threatened either their own future health or the health of their family,” said Dr. Carter. “These life and family-related concerns are poorly studied so far in trials in glomerular disease, but they are more important to patients and caregivers than other commonly reported outcomes such as relapse, remission, and proteinuria.”
This study is part of the international Standardized Outcomes in Nephrology–Glomerular Disease project (SONG-GD) that is developing a core outcome set for clinical trials in adults with glomerular disease. A core outcome set is a small number of outcomes that should be reported in all trials in a particular health domain because that knowledge is critically important to all stakeholders and users of the research. SONG-GD is part of the SONG initiative (https://songinitiative.org), which was launched in 2014 to develop core outcome sets for trials in all kidney diseases. “With the help of many international patient and professional organizations, the SONG initiative has now involved more than 9,000 participants internationally across its various streams—including 4,500 patients and caregivers, but also healthcare professionals such as doctors, nurses, allied health, researchers and industry partners, policy makers, funders, and regulators,” said Dr. Carter.
Study co-authors include Talia Gutman MPH, Charlotte Logeman MPH, Dan Cattran MD, Liz Lightstone MBBS, Arvind Bagga MD, Sean J. Barbour MD, Jonathan Barratt PhD, John Boletis MD, Dawn Caster MD, Rosanna Coppo MD, Fernando C. Fervenza PhD, Jürgen Floege MD, Michelle Hladunewich MD, Jonathan J. Hogan MD, A. Richard Kitching PhD, Richard A. Lafayette MD, Ana Malvar MD, Jai Radhakrishnan MD, Brad H. Rovin MD, Nicole Scholes-Robertson BAppS, Hérnan Trimarchi MD, Hong Zhang PhD, Karolis Azukaitis MD, Yeoungjee Cho PhD, Andrea K. Viecelli PhD, Louese Dunn MPH, David Harris MD, David W. Johnson PhD, Peter G. Kerr PhD, Paul Laboi MBBS, Jessica Ryan PhD, Jenny I. Shen MD, Lorena Ruiz, Angela Yee-Moon Wang MD, Achilles Hoi Kan Lee MD, Samuel Fung Ka Shun MBBS, Matthew Ka-Hang Tong MBBS, Armando Teixeira-Pinto PhD, Martin Wilkie MD, Stephen I. Alexander MD MPH, Jonathan C. Craig PhD, and Allison Tong PhD, on behalf of the SONG-GD Investigators.
Disclosures: SONG-GD is supported by a National Health and Medical Research Council (NHMRC) Program Grant (1092957). SAC is supported by the NHMRC Post-graduate Scholarship (1168994). DJC is supported by grant K08DK102542 from the NIH. YC is supported by the NHMRC Early Career Fellowship (1126256). TG is supported by a NHMRC Post-graduate scholarship (1169149). DJ is supported by a NHMRC Practitioner Fellowship (1117534). JIS is supported by grant K23DK103972 from the National Institutes of Health (NIH). ATP is supported by a NHMRC Career Development Fellowship (1106716). AKV received grant support from the NHMRC Medical Postgraduate Scholarship (1114539).
The article, entitled “Identifying Outcomes Important to Patients with Glomerular Disease and their Caregivers,” will appear online at http://cjasn.asnjournals.org/ on April 30, 2020, doi: 10.2215/CJN.13101019.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.
# # #
MEDIA CONTACTRegister for reporter access to contact details